26
Feb
2018
The Henri A. Termeer Tribute: An Uplifting Idea for a Tumultuous Time
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
23
Feb
2018
Gilead’s Latest CAR-T Domino, Takeda’s Deal Spree, & Merck’s Oncolytics Bet
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
20
Feb
2018
Through the Looking Glass with PheWAS
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
16
Feb
2018
All-Star Lineup for Boston Cancer Summit, March 7: Novartis, J&J, Third Rock, Atlas
Timmerman Report is bringing together major East Coast cancer R&D players for an intimate half-day event on March 7: the Boston Cancer Summit. Join an all-star gathering of pharma executives, hot startups, and VCs making things happen in the treatment and diagnosis of cancer. Tickets are sold out. The conference will be at Sanofi Genzyme’s flagship building in the heart of Kendall Square.... Read More
15
Feb
2018
Mingle in Seattle with Genentech, Celgene, OrbiMed, 5AM & More, March 5
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
14
Feb
2018
Building a Cancer R&D Engine To Last: David Schenkein on The Long Run
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
9
Feb
2018
BMS Makes Case for TMB, Express Scripts Sees Drug Price Slowdown, & Theravance Pockets $100M
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
5
Feb
2018
The Caveman’s Guide to Productivity
One TR subscriber already knew about some of my quirks: he and I rode in a van together for 26 hours straight to do the 200-mile Ragnar Reach the Beach Relay in New Hampshire. But when I published last month’s column detailing my Everest training, he wanted to know more. “I study performance pretty carefully, so all these kinds of questions fascinate... Read More
2
Feb
2018
Amazon Sizes Up Healthcare Beast, Vertex Raises the Bar in CF, Moderna Hauls in Another $500M
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
31
Jan
2018
Big Idea, Big Money, Big Skepticism: The Long Run Podcast With Stephane Bancel
Today’s guest on The Long Run is Stephane Bancel. He’s the CEO of Cambridge, Mass.-based Moderna Therapeutics. The company, and the man at the helm, are somewhat controversial. Google Bancel’s name, and the ‘People Also Search For’ window shows famous entrepreneurs like Jeff Bezos, Elon Musk…and Elizabeth Holmes of Theranos infamy. Each situation for those entrepreneurs is different, and comparisons... Read More
30
Jan
2018
State Laws Zero in On Rising Drug Costs
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
29
Jan
2018
The Boston Cancer Summit & Seattle Cancer Summit. Two Can’t-Miss Events
Cancer wasn’t that exciting to write about when I started 15 years ago. It is now. Survival rates for several forms of cancer are going in the right direction. Immunotherapy, targeted therapy, new information on genes and proteins that redefine the molecular nature of malignancy? It’s coming together. The science is bursting with creativity, and moving fast. I’m thinking and... Read More
26
Jan
2018
Celgene Pulls the Trigger for Juno, Azar Confirmed, & Half-Hearted Gene Editing
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
23
Jan
2018
Leveraging June’s I-O Team at Penn, Tmunity Fetches $100M from Gilead, Parker & Ping An
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
22
Jan
2018
Lessons in Digging Deep (January Update: Everest Climb to Fight Cancer at Fred Hutch)
Many of you have a big dream. Many of you have your own “Everest” – a big, hairy audacious goal that will take serious time and sacrifice to achieve. I deeply admire those of you doing your best to move the needle for human health, whether it’s for cancer or some other serious illness. When the going gets tough, you... Read More
19
Jan
2018
Celgene’s Rumored Juno Talks, Hospitals Shoot at Generic Drugmakers, & Keytruda Hits a Phase III
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
18
Jan
2018
Reverse Engineering I-O Bispecifics for Autoimmunity, Pandion Snags $58M
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
17
Jan
2018
Getting a Seat at the Table: The Long Run Podcast With Abbie Celniker
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Jan
2018
Celgene Gets a JAK2 for $1.1B, Novo Bids for Ablynx & Pfizer Drops Neuro: Pre#JPM18 Wrap
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
5
Jan
2018
Spark Sets $850K Bar, Microsoft’s Bet on AI for Immune Mapping, & Startup Financings Galore
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.